WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

236.19 USD
+2.36 (+1.01%)
Last: Mar 11, 2026, 12:49 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall WST gets a fundamental rating of 6 out of 10. We evaluated WST against 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making WST a very profitable company, without any liquidiy or solvency issues. WST is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. WST Profitability Analysis

1.1 Basic Checks

  • In the past year WST was profitable.
  • In the past year WST had a positive cash flow from operations.
  • WST had positive earnings in each of the past 5 years.
  • In the past 5 years WST always reported a positive cash flow from operatings.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • WST's Return On Assets of 11.56% is amongst the best of the industry. WST outperforms 92.98% of its industry peers.
  • WST's Return On Equity of 15.54% is amongst the best of the industry. WST outperforms 89.47% of its industry peers.
  • WST's Return On Invested Capital of 14.09% is amongst the best of the industry. WST outperforms 92.98% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for WST is above the industry average of 11.85%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 14.09%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • WST's Profit Margin of 16.06% is amongst the best of the industry. WST outperforms 84.21% of its industry peers.
  • In the last couple of years the Profit Margin of WST has remained more or less at the same level.
  • WST has a Operating Margin of 20.53%. This is amongst the best in the industry. WST outperforms 87.72% of its industry peers.
  • In the last couple of years the Operating Margin of WST has remained more or less at the same level.
  • The Gross Margin of WST (35.91%) is worse than 61.40% of its industry peers.
  • In the last couple of years the Gross Margin of WST has remained more or less at the same level.
Industry RankSector Rank
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. WST Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so WST is still creating some value.
  • Compared to 1 year ago, WST has less shares outstanding
  • The number of shares outstanding for WST has been reduced compared to 5 years ago.
  • WST has a better debt/assets ratio than last year.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • WST has an Altman-Z score of 12.25. This indicates that WST is financially healthy and has little risk of bankruptcy at the moment.
  • WST has a Altman-Z score of 12.25. This is amongst the best in the industry. WST outperforms 98.25% of its industry peers.
  • WST has a debt to FCF ratio of 0.44. This is a very positive value and a sign of high solvency as it would only need 0.44 years to pay back of all of its debts.
  • The Debt to FCF ratio of WST (0.44) is better than 92.98% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that WST is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.06, WST is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Altman-Z 12.25
ROIC/WACC1.3
WACC10.84%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • WST has a Current Ratio of 3.02. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • WST's Current ratio of 3.02 is in line compared to the rest of the industry. WST outperforms 56.14% of its industry peers.
  • A Quick Ratio of 2.34 indicates that WST has no problem at all paying its short term obligations.
  • WST's Quick ratio of 2.34 is in line compared to the rest of the industry. WST outperforms 54.39% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. WST Growth Analysis

3.1 Past

  • WST shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 8.00%.
  • WST shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.94% yearly.
  • Looking at the last year, WST shows a small growth in Revenue. The Revenue has grown by 6.25% in the last year.
  • WST shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.44% yearly.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • WST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.50% yearly.
  • The Revenue is expected to grow by 5.60% on average over the next years.
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue Next Year6.01%
Revenue Next 2Y6.04%
Revenue Next 3Y6.31%
Revenue Next 5Y5.6%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 32.40, the valuation of WST can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of WST is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Earnings ratio of 26.25, WST is valued a bit more expensive.
  • A Price/Forward Earnings ratio of 29.15 indicates a quite expensive valuation of WST.
  • 61.40% of the companies in the same industry are more expensive than WST, based on the Price/Forward Earnings ratio.
  • WST's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.39.
Industry RankSector Rank
PE 32.4
Fwd PE 29.15
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of WST indicates a somewhat cheap valuation: WST is cheaper than 70.18% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, WST is valued a bit cheaper than 63.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.28
EV/EBITDA 20.26
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of WST may justify a higher PE ratio.
PEG (NY)2.91
PEG (5Y)3.62
EPS Next 2Y11.07%
EPS Next 3Y11.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. WST Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.32%, WST is not a good candidate for dividend investing.
  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.10. WST pays more dividend than 84.21% of the companies in the same industry.
  • With a Dividend Yield of 0.32, WST pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 12.40% of the earnings are spent on dividend by WST. This is a low number and sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.4%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (3/11/2026, 12:49:07 PM)

236.19

+2.36 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.62%
Inst Owner Change-2.08%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap17.01B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (39.29%)
Short Float %3.13%
Short Ratio2.33
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-6.91%
PT rev (3m)-5.85%
EPS NQ rev (1m)1.65%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)3.22%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)2.4%
Revenue NQ rev (3m)2.48%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 32.4
Fwd PE 29.15
P/S 5.53
P/FCF 36.28
P/OCF 22.54
P/B 5.36
P/tB 5.56
EV/EBITDA 20.26
EPS(TTM)7.29
EY3.09%
EPS(NY)8.1
Fwd EY3.43%
FCF(TTM)6.51
FCFY2.76%
OCF(TTM)10.48
OCFY4.44%
SpS42.68
BVpS44.1
TBVpS42.47
PEG (NY)2.91
PEG (5Y)3.62
Graham Number85.05
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.45%
ROIC 14.09%
ROICexc 18.03%
ROICexgc 18.82%
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2103.33
Cash Conversion 94.07%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 12.25
F-Score7
WACC10.84%
ROIC/WACC1.3
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.01%
Revenue Next 2Y6.04%
Revenue Next 3Y6.31%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.23%
EBIT Next 3Y19.91%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.